Business Development

Partnerships

Autonomous University of Barcelona

Ability Pharmaceuticals has a research collaboration with Dr. José Miguel Lizcano's laboratory at the Department of Biochemisty, Faculty of Medicine of the Autonomous University of Barcelona, in Bellaterra.

Vall d'Hebron Institut d’Oncologia

Ability Pharmaceuticals Phase II clinical studies performed at the Department of Oncology at the Vall d'Hebron University Hospital. Dr. Ana Oaknin is the Principal Investigator.

SciClone Pharmaceuticals, Inc.

In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with the NASDAQ US company SciClone Pharmaceuticals to develop and market the product in Greater China, with upfront and milestone payments over $ 20 M

IDIBAPS

Ability Pharmaceuticals has research collaborations with the Area of Molecular and Translational Oncology of the IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), associated with the Hospital Clinic de Barcelona and the University of Barcelona. The Area is led by Dr. Pere Gascon.

Hospital Clínic de Barcelona

Ability Pharmaceuticals conducted the Phase I/Ib clinical trials at the Medical Oncology Service and at the Clinical Institute of Hemato-Oncological Diseases y (ICMHO) of the Hospital Clinic de Barcelona. Dr. Laura Vidal was the Principal Investigator.

Institut Catala d'Oncologia

Ability Pharmaceuticals perform the phase II clinical studies in the Catalan Institute of Oncology (ICO) in the centers of L'Hospitalet, Girona and Badalona. Dr. Ernest Nadal, Dr. Joaquim Bosch and Dr. Teresa Moran are the principal investigators, respectively.

University of Girona


Ability Pharmaceuticals has a research collaboration with Dr. Teresa Puig's laboratory at the Department of Molecular Oncology, Faculty of Medicine of the University of Girona (Catalonia).

Universitat de Lleida

Ability Pharmaceuticals has a research collaboration with Dr. Xavier Matias-Guiu, head of pathological anatomy at Bellivtge Hosptial and Arnau de Vilanova Hospital and director of Biomedical Research Institute of Lleida (IRB). The collaboration also includes Dra. Nuria Eritja, head of the pathological laboratory and oncology group at IRB, and Dra. Eva Colàs, principal investigator currently in Vall d’Hebron Institut de Recerca (VHIR), Barcelona.

Vall d'Hebron Research Institute


Ability Pharmaceuticals has a research collaboration with Dr. Miguel Segura's laboratory of the Tranlational Research in Pediatric Carcer Group of the Vall d’Hebron Institut de Recerca (VHIR), Barcelona.

Medalchemy

Medalchemy has developed the synthetic routes of the drug candidates being developed by Ability Pharmaceuticals and is proceeding to the escalation of their production.
 
Medalchemy is base at the Science Park of the University of Alicante/Alacant.
 

European Network for the Study of Cholangiocarcinoma

We belong to the ENS-CCA, a group of active researchers with a broad interest in cholangiocarcinoma clinical area, which has significantly contributed to the study into the pathophysiology of the biliary tree and development/onset of cholangiocarcinoma, and pursuing basic, translational and clinical research in an effort to identify treatment options with successful outcome for this type of cancer. 

LATEST NEWS

11.03.2024

Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
02.11.2022

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info
07.10.2022

Press Release

AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info
07.09.2022

Press Release

Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info
29.06.2022

Press Release

AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG